arrow Log In to View Account     |          


Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

This live broadcast will provide live credit (L) for those states requiring it.

Though non-vitamin K antagonist oral anticoagulants (NOACs) have surpassed warfarin as the treatment of choice for nonvalvular atrial fibrillation (NVAF) by both patients and clinicians, NOACs remain underutilized largely due to cost and insurance-related barriers. NOACs overcome a number of limitations associated with warfarin and demonstrate comparable, if not superior, efficacy; they exhibit fewer drug-drug interactions and patients undergo either limited or no laboratory monitoring during treatment. Recently published comparative data regarding efficacy/safety and cost, as well as the development of reversal strategies, provide much anticipated evidenced-based data to address many of the longstanding clinical uncertainties that have contributed to restrictive access. This live activity, in the form of a mock live P&T committee meeting, will feature 4 managed care pharmacy experts who will discuss the value of NOACs and how they may be better utilized to realize both their clinical and economic benefits.

The goal of this activity is to provide managed care pharmacists, including pharmacy directors, with the evidence-based clinical and real-world data on NOACs compared to warfarin to use in NOAC formulary decision-making.

This activity is designed to meet the needs of managed care pharmacists, including pharmacy directors, nationwide. No prerequisites required.

  • Preassessment
  • Introduction
    Sheldon J. Rich, RPh, PhD
  • NOACs in NVAF – Clinical Promises, Coverage Challenges, and Real-World Data
    Paul P. Dobesh, PharmD, FCCP, BCPS
    - Barriers to adequate anticoagulation/thromboprophylaxis and limitations of warfarin therapy
    - Overview of clinical trial data on efficacy and safety of NOACs
    - Indication differences
  • Mock P&T Committee Discussion
    Faculty Panel
  • - The impact of restrictive coverage on providers and patients
    - Components of cost-effectiveness analyses for warfarin and NOACs
  • Postassessment and Evaluation
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
  • CONTRAST the benefits and risks of NOACs versus traditional warfarin therapy as demonstrated by clinical trial and real-world data.
  • DIFFERENTIATE efficacy and safety of available agents in the NOAC class.
  • EVALUATE varying cost implications associated with formulary decision making regarding NOACs for NVAF and other indications.
Sheldon J. Rich, RPh, PhD (Chair)
President - SJR Associates, LLC
Adjunct Clinical Assistant Professor - University of Michigan
Adjunct Assistant Professor - Wayne State University
Palm Beach Gardens, FL

Paul P. Dobesh, PharmD, FCCP, BCPS
AQ Cardiology
Professor of Pharmacy Practice
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska

Jeffrey D. Dunn, PharmD, MBA
Vice President, Pharmacy
Magellan Rx
Salt Lake City, Utah

James T. Kenney, RPh, MBA
Manager, Specialty and Pharmacy Contracts
Harvard Pilgrim Health Care
Wellesley, Massachusetts

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based activity will provide a statement for 1.5 live contact hours of credit (0.15 CEUs). Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-17-220-L01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website:
To receive credit for your participation in this activity, all pharmacists must include their CORRECT NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.

A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

There is no fee for this educational activity.

University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by ASiM CE, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC.